RevolutionLogo.png
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
November 10, 2021 16:05 ET | Revolution Medicines, Inc.
RAS(ON) Inhibitor Development Candidates Targeting KRASG12C and RASMULTI Progressing Toward the Clinic; Company Showed Additional Preclinical Data Supporting Benefits and Differentiation Company...
22157.jpg
RAS Targeting Therapies Market, 2031
November 09, 2021 06:03 ET | Research and Markets
Dublin, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The "RAS Targeting Therapies by Target Indication, Type of Molecule, Type of Therapy, and Route of Administration, Key Geographical Regions: Industry Trends...
RevolutionLogo.png
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
November 08, 2021 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
RevolutionLogo.png
Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
November 03, 2021 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
RevolutionLogo.png
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
RevolutionLogo.png
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
September 15, 2021 07:30 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
RevolutionLogo.png
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
RevolutionLogo.png
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
August 11, 2021 16:01 ET | Revolution Medicines, Inc.
Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic Initial Results of RMC-4630-02 Study...
RevolutionLogo.png
Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
August 04, 2021 16:05 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit...
logo.gif
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
July 06, 2021 09:00 ET | Auris Medical AG
Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission...